2-(R)-[1-(3,4-dimethoxy-phenyl)-pent-4-enyl]-4-(4-ethyl-piperazin-1-yl)-2,3-dihydro-isoindol-1-one | 1184872-09-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 2-(R)-[1-(3,4-dimethoxy-phenyl)-pent-4-enyl]-4-(4-ethyl-piperazin-1-yl)-2,3-dihydro-isoindol-1-one
• 英文别名: 2-[1-(R)-(3,4-dimethoxy-phenyl)-pent-4-enyl]-4-(4-ethyl-piperazin-1-yl)-2,3-dihydro-isoindol-1-one；2-[(1R)-1-(3,4-dimethoxyphenyl)pent-4-enyl]-4-(4-ethylpiperazin-1-yl)-3H-isoindol-1-one
• CAS: 1184872-09-0
• 化学式: C₂₇H₃₅N₃O₃
• 分子量: 449.593
• InChiKey: SKEBVYGOJNIFIJ-HSZRJFAPSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  33
• 可旋转键数：
  9
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  45.2
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2-(R)-[1-(3,4-dimethoxy-phenyl)-pent-4-enyl]-4-(4-ethyl-piperazin-1-yl)-2,3-dihydro-isoindol-1-one 在 9-硼双环[3.3.1]壬烷 、 水 、 双氧水 、 sodium hydroxide 作用下， 以 四氢呋喃 为溶剂， 生成 2-[1-(R)-(3,4-Dimethoxy-phenyl)-5-hydroxy-pentyl]-4-(4-ethyl-piperazin-1-yl)-2,3-dihydro-isoindol-1-one
  参考文献：
  名称：

  UROTENSIN II RECEPTOR ANTAGONISTS

  摘要：

  本发明涉及式(I)化合物及其药学上可接受的盐、酯和前药，含有式(I)化合物的药物组合物以及将所述化合物和组合物用作尿激肽II受体拮抗剂的用途。

  公开号：

  US20100029616A1
• 作为产物：
  描述：

  4-(R)-(3,4-dimethoxy-phenyl)-4-[4-(4-ethyl-piperazin-1-yl)-1-oxo-1,3-dihydro-isoindol-2-yl]-butyraldehyde 在 18-冠醚-6 、 甲基三苯基溴化膦 作用下， 以 二氯甲烷 为溶剂， 以34%的产率得到2-(R)-[1-(3,4-dimethoxy-phenyl)-pent-4-enyl]-4-(4-ethyl-piperazin-1-yl)-2,3-dihydro-isoindol-1-one
  参考文献：
  名称：

  Generation of novel, potent urotensin-II receptor antagonists by alkylation–cyclization of isoindolinone C3-carbanions

  摘要：

  We report a facile alkylation-cyclization reaction involving the isoindolinone C3 position, which resulted in tricyclic derivatives 2 and 10 in 48% and 32% yields, respectively. These novel compounds possess potent urotensin-II receptor antagonist activity. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2009.06.025

文献信息

• UROTENSIN II RECEPTOR ANTAGONISTS
  申请人：Kinney William A.

  公开号：US20100029616A1

  公开（公告）日：2010-02-04

  The present invention is directed to compounds of formula (I) and pharmaceutically acceptable salts, esters and prodrugs thereof, pharmaceutical compositions containing compounds of formula (I) and the use of said compounds and compositions as urotensin II receptor antagonists.

  本发明涉及式(I)化合物及其药学上可接受的盐、酯和前药，含有式(I)化合物的药物组合物以及将所述化合物和组合物用作尿激肽II受体拮抗剂的用途。
• US9079896B2
  申请人：——

  公开号：US9079896B2

  公开（公告）日：2015-07-14
• [EN] UROTENSIN II RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DE RÉCEPTEUR D'UROTENSINE II
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2010017105A1

  公开（公告）日：2010-02-11

  The present invention is directed to compounds of formula (I) and pharmaceutically acceptable salts, esters and prodrugs thereof, pharmaceutical compositions containing compounds of formula (I) and the use of said compounds and compositions as urotensin Il receptor antagonists.
• Generation of novel, potent urotensin-II receptor antagonists by alkylation–cyclization of isoindolinone C3-carbanions
  作者：Diane K. Luci、Edward C. Lawson、Shyamali Ghosh、William A. Kinney、Charles E. Smith、Jenson Qi、Yuanping Wang、Lisa K. Minor、Bruce E. Maryanoff

  DOI：10.1016/j.tetlet.2009.06.025

  日期：2009.9

  We report a facile alkylation-cyclization reaction involving the isoindolinone C3 position, which resulted in tricyclic derivatives 2 and 10 in 48% and 32% yields, respectively. These novel compounds possess potent urotensin-II receptor antagonist activity. (C) 2009 Elsevier Ltd. All rights reserved.